Clinical Oncology Specialist
CurrentPromote the adoption and utilization of Molecular Residual Disease Monitoring (MRD) of solid tumors by ctDNA via PCR built from SNVs identified through whole exome and whole transcriptome NGS of solid tumors with a germline control. -SignateraHighlight the complimentary testing advantages of CGP and Germline as an efficient, tissue-sparing option to deliver tumor-informed MRD monitoring as well as high-quality DNA & RNA CGP for somatic mutations and Germline testing for Hereditary Cancer Risk Evaluation. Highlight the use cases, and the advantages of ctDNA vs conventional methods like Cancer Antigen tests or Imaging studies to track tumor response and recurrence.Collaborate with both internal and external partners to meet objectives, integrations goals, and improve patient outcomes.
